Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
11.42
-0.33 (-2.81%)
At close: Sep 28, 2026, 4:00 PM EDT
11.49
+0.07 (0.61%)
Pre-market: Sep 29, 2026, 7:47 AM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$157,841
Profits / Employee
-$1,060,942
Market Cap
1.60B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Syndax Pharmaceuticals | 298 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Absci | 140 |
| Septerna | 123 |
| Nanobiotix | 100 |
NTLA News
- 14 days ago - Intellia Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 19 days ago - Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today - TheFly
- 19 days ago - Intellia Therapeutics price target raised to $13 from $12 at Wedbush - TheFly
- 20 days ago - Intellia Therapeutics announces FDA acceptance of lonvo-z BLA - TheFly
- 21 days ago - Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - GlobeNewsWire
- 24 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - GlobeNewsWire
- 25 days ago - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire